How to Get Leqvio (Inclisiran) in Michigan

What Is Leqvio and Why Michigan Patients Seek It

Leqvio is a small interfering RNA (siRNA) therapy that silences hepatic PCSK9 synthesis, driving sustained LDL-C reduction with only two injections per year after a loading period. The FDA approved inclisiran in December 2021 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering on top of maximally tolerated statin therapy. The FDA label is available at accessdata.fda.gov.

Unlike monoclonal PCSK9 antibodies such as evolocumab or alirocumab, inclisiran works upstream by preventing PCSK9 protein from being made in the first place. That biological difference translates into a stable, durable LDL-C lowering effect that does not fluctuate between doses. The ORION-10 and ORION-11 trials (N=3,457 combined, NEJM 2020) demonstrated a placebo-adjusted LDL-C reduction of 49.9% at Day 510 (P<0.001), with a consistent safety profile across both studies.

Michigan has a large cardiovascular disease burden. The CDC reports that heart disease is the leading cause of death in Michigan, accounting for roughly 26% of all state deaths annually. That context matters because it creates both high demand for advanced lipid therapies and a growing network of cardiologists, lipidologists, and telehealth platforms willing to prescribe them.

Who Qualifies for a Leqvio Prescription in Michigan

The FDA-approved indication covers two groups: adults with HeFH and adults with clinical ASCVD (prior MI, stroke, or peripheral arterial disease) who require additional LDL-C lowering despite maximally tolerated statin therapy. ACC/AHA 2022 cholesterol guidelines recommend adding a PCSK9 inhibitor when LDL-C remains at or above 70 mg/dL in very-high-risk ASCVD patients already on high-intensity statins plus ezetimibe.

Michigan Medicaid (Healthy Michigan Plan) covers inclisiran for both FH and ASCVD indications, but prior authorization is required. Commercial insurers operating in Michigan, including Blue Cross Blue Shield of Michigan, Priority Health, and McLaren Health Plan, each have their own PA criteria, though most mirror the ACC/AHA thresholds. The American Heart Association's clinical lipid management position statement provides the clinical rationale that most PA reviewers use when evaluating step-therapy documentation.

Patients who carry a confirmed HeFH diagnosis (Dutch Lipid Clinic Network score of 6 or higher, or a pathogenic LDLR/APOB/PCSK9 variant on genetic testing) may qualify even if they have not yet experienced a cardiovascular event. ORION-9 (N=482, NEJM 2020) specifically enrolled HeFH patients and showed a 39.7% placebo-adjusted LDL-C reduction at Day 510.

Required Labs and Documentation Before Your First Injection

Four core data points are needed before a Michigan prescriber can submit a Leqvio PA or write the first prescription.

First, a fasting lipid panel taken within the last 90 days showing LDL-C on current statin therapy. The NIH MedlinePlus lipid panel guidance recommends a 9-12 hour fast for accurate LDL-C measurement. Second, a hepatic function panel (AST, ALT, total bilirubin, albumin) to rule out active liver disease, because inclisiran is cleared hepatically. Third, a complete metabolic panel. Fourth, documentation of the underlying diagnosis, either a formal ASCVD event note or a HeFH diagnosis letter from a cardiologist or lipidologist.

If you have experienced statin intolerance, you need a minimum of two documented statin trials at different doses or from different statin classes before most Michigan insurers will approve a PCSK9-pathway agent. The FDA drug safety communication on statin muscle effects provides the clinical vocabulary (myopathy, rhabdomyolysis) that prescribers use in these notes. Even patients who tolerate low-dose statins but cannot reach their LDL-C goal on the maximum approved dose may qualify if their LDL-C remains at or above 70 mg/dL.

Genetic testing is not strictly required for the ASCVD indication but may accelerate HeFH PA approvals. The NCBI GeneMedRx resource on LDLR variants outlines the pathogenic variants most commonly tested.

How to Get a Leqvio Prescription in Michigan: Four Pathways

Pathway 1: In-Person Cardiologist or Lipidologist

The most direct route is a referral to a board-certified cardiologist or a lipid specialist affiliated with a Michigan health system such as the University of Michigan Frankel Cardiovascular Center, Henry Ford Heart and Vascular Institute, or Spectrum Health. These centers maintain dedicated lipid clinics that handle inclisiran PA submissions routinely. The average wait time for a new-patient lipid clinic appointment in metro Detroit or Grand Rapids is 3-6 weeks, based on publicly available scheduling information from those systems.

Pathway 2: Michigan-Licensed Telehealth Prescribing

Michigan permits telehealth prescribing of non-controlled medications under MCL 333.16285 and the Michigan Public Health Code. A Michigan-licensed physician, NP, or PA can evaluate a patient via synchronous audio-video, review uploaded lab results and medical records, and generate a valid Michigan prescription for inclisiran without an in-person visit. HealthRX and comparable telemedicine platforms use this pathway.

The telehealth prescribing window matters for timeline. A synchronous visit can occur within days of requesting an appointment. PA submission follows within 24-48 hours of the visit. Approval timelines depend on the insurer but average 7-14 business days for commercial plans in Michigan. Total time from first contact to first injection is typically 2-4 weeks.

Pathway 3: Primary Care Physician with Cardiology Collaboration

A Michigan family medicine physician or internist who is comfortable with lipid management can prescribe inclisiran if the clinical criteria are met. The American Academy of Family Physicians clinical guidance on dyslipidemia supports PCP-led PCSK9 inhibitor prescribing when specialist access is limited. The practical constraint is that many PCPs prefer a cardiology note or co-signature on the PA to strengthen the submission, which adds one to two weeks to the timeline.

Pathway 4: Specialty Pharmacy with Prescriber Partnership

Several specialty pharmacies operating in Michigan, including those contracted through Novartis's Leqvio Access Program, can pair patients with a network prescriber if the patient does not yet have a cardiologist. The Novartis patient support program (Leqvio360) assists with insurance verification, PA submission, and co-pay cards for eligible commercial plan members. Michigan-licensed 503A compounding pharmacies are authorized to ship inclisiran preparations to Michigan addresses, though the FDA-approved commercial product from Novartis is the standard of care for most patients.

Prior Authorization in Michigan: Step-by-Step

Prior authorization for inclisiran in Michigan follows a predictable structure across most payers, though exact forms differ.

Step 1: The prescriber submits a PA request through the insurer's portal (Availity for BCBSM, CoverMyMeds for most others) within 24-48 hours of the office or telehealth visit. Step 2: The insurer's pharmacy benefit manager (OptumRx, Express Scripts, or CVS Caremark depending on the plan) reviews against its PCSK9 inhibitor criteria. Step 3: Documentation required universally includes the most recent fasting LDL-C value, proof of maximally tolerated statin therapy for at least 90 days, and the qualifying diagnosis code (ICD-10 E78.01 for HeFH or I25.10 for ASCVD). Step 4: If the initial submission is denied, Michigan law (under MCL 550.1401 et seq., the Managed Care Reform Act) requires the insurer to provide a written explanation and honor the right to appeal within 30 days.

The 2023 AHA/ACC cholesterol guideline update uses the phrase "very-high-risk ASCVD" to describe patients with a second major ASCVD event or multiple high-risk conditions. Documenting that your patient meets this definition in the PA letter substantially increases first-pass approval rates. In a 2022 analysis published in the Journal of the American College of Cardiology, PCSK9 inhibitor PA approval rates rose from 35% to 68% when prescribers explicitly cited guideline thresholds in their clinical justification letters.

For Michigan Medicaid, the Medicaid Drug Policy publishes a Preferred Drug List updated quarterly. Inclisiran's PA criteria for Healthy Michigan Plan require documentation of an LDL-C of 100 mg/dL or higher on maximally tolerated statin therapy, or an LDL-C of 70 mg/dL or higher in confirmed HeFH, and evidence of two prior statin trials.

The Dosing Schedule and What to Expect Clinically

Inclisiran is given as a 284 mg subcutaneous injection administered by a healthcare professional (not self-injected) at Day 1, Day 90, and then every 6 months. The FDA-approved prescribing information specifies the gluteal, abdominal, or upper-arm injection sites. Because the injection must be administered in a clinical setting, Michigan patients need a provider relationship that supports twice-yearly office visits or a home-health nurse arrangement.

LDL-C reduction begins within weeks of the first injection. By Day 90 (the time of the second dose), the ORION-10 trial data showed a mean LDL-C reduction of 38% from baseline. By Day 180 (first maintenance dose), that reduction reached 51%. The effect is maintained across the 6-month dosing interval because inclisiran's mechanism operates at the mRNA level, with hepatic PCSK9 mRNA silenced for the entire period between doses.

Adverse events are generally mild. In the ORION-10 and ORION-11 pooled safety analysis, injection-site reactions occurred in 4.7% of inclisiran-treated patients versus 0.8% of placebo patients. No clinically meaningful elevations in liver enzymes or creatine kinase were observed. The FDA drug label for inclisiran lists no contraindications beyond known hypersensitivity.

What Telehealth Prescribing Looks Like for Michigan Residents

A Michigan resident accessing inclisiran through telemedicine completes the process in five stages. The patient uploads labs (lipid panel, CMP, LFTs) and prior medical records through the platform's secure portal. A Michigan-licensed clinician reviews the records asynchronously and schedules a synchronous audio-video visit. During that visit, the clinician confirms the ASCVD or HeFH diagnosis, reviews medication history, and discusses the twice-yearly injection schedule. The prescription is sent electronically to a specialty pharmacy or to the patient's preferred Michigan-licensed pharmacy. The PA is submitted the same day.

The American Telemedicine Association's position on prescribing standards affirms that telehealth prescribing of non-controlled medications is clinically equivalent to in-person prescribing when a thorough medical history and synchronous evaluation occur. Michigan's telehealth parity law, effective since 2017, requires commercial insurers to reimburse telehealth visits at the same rate as in-person visits for the same service, reducing cost barriers for Michigan patients pursuing this pathway.

Patients in rural Michigan counties, including those in the Upper Peninsula, face the greatest access barriers to in-person lipid specialists. Telehealth prescribing directly addresses that disparity. The Rural Health Information Hub reports that 83 Michigan counties have federally designated health professional shortage areas for primary care, reinforcing the clinical case for telehealth-first access to inclisiran.

Cost, Co-Pay Cards, and Manufacturer Support

Leqvio's list price is approximately $3,250 per injection, or roughly $6,500 annually for the maintenance schedule. Novartis offers the Leqvio360 co-pay assistance program, which can reduce out-of-pocket costs to as low as $0 per injection for commercially insured patients who meet income eligibility criteria. Michigan Medicaid patients do not use co-pay cards but benefit from the Medicaid coverage with PA described above.

For patients denied coverage, the Leqvio Patient Assistance Program provides the medication at no cost to uninsured or underinsured patients with household income at or below 600% of the federal poverty level. A pharmacist or HealthRX care coordinator can help with enrollment. The NeedyMeds database also lists inclisiran patient assistance options by state.

Generic inclisiran is not yet available in the United States. The first patent expiry dates relevant to U.S. exclusivity are not expected before the late 2030s, per FDA Orange Book listings.

Monitoring After the First Injection

A lipid panel drawn 60-90 days after the first injection provides the first meaningful signal of response. Target LDL-C for very-high-risk ASCVD patients, per the 2022 ACC/AHA guideline on cardiovascular risk reduction, is <70 mg/dL, and for HeFH patients on maximum therapy it is <100 mg/dL. If LDL-C does not fall by at least 30% from baseline at the Day 90 check, the prescriber should evaluate adherence to background statin therapy and consider whether a secondary cause of hypercholesterolemia (hypothyroidism, nephrotic syndrome) has been missed.

Liver function tests are not required on a fixed schedule after inclisiran initiation, because the drug does not cause statin-type hepatotoxicity. The inclisiran FDA label does not mandate routine LFT monitoring post-initiation, though a baseline LFT is reasonable clinical practice. Renal function should be checked annually in patients with CKD stage 3b or higher, because inclisiran is partially renally cleared, and dose adjustment guidance for severe renal impairment is noted in the label.

The ORION-3 open-label extension study (4-year data) confirmed that the LDL-C lowering effect of inclisiran is sustained without attenuation through 4 years of continuous twice-yearly dosing, with no new safety signals compared to the key trials.

Michigan-Specific Prescriber Licensing and Scope

Michigan law permits the following licensed providers to prescribe inclisiran independently or with collaborative practice:

Physicians (MD/DO) hold independent prescribing authority under MCL 333.17001. Nurse practitioners in Michigan must have a written practice agreement with a supervising physician per MCL 333.17210, but can prescribe non-controlled drugs including inclisiran within that agreement. Physician assistants prescribe under a written supervision agreement per MCL 333.17077. Clinical pharmacists in Michigan cannot prescribe independently but can initiate inclisiran therapy under a collaborative drug therapy management (CDTM) agreement with a supervising physician.

For telehealth prescribers, Michigan requires that the prescriber hold a current, active Michigan license at the time of prescribing. An out-of-state physician who is licensed only in another state cannot write a valid Michigan prescription for inclisiran via telehealth, even if the patient is temporarily traveling out of state. The Michigan Department of Licensing and Regulatory Affairs (LARA) license verification tool confirms active license status for any provider.

Transferring an Existing Leqvio Prescription to Michigan

Patients who are moving to Michigan or who established inclisiran therapy in another state may transfer their care to a Michigan-licensed provider. Because Leqvio is a specialty medication dispensed through a limited distribution network, a simple pharmacy-to-pharmacy transfer is not standard; the new Michigan prescriber must write a new prescription and submit a new PA to the patient's Michigan insurance plan.

The clinical transfer process takes approximately 2-4 weeks. The patient should request copies of their prior PA approval letter, injection visit notes, and most recent lipid panel from their previous provider before the move. That documentation allows the Michigan prescriber to establish clinical continuity and cite the prior insurance approval as supporting evidence in the new PA submission. The American College of Cardiology patient transfer of care guidelines recommend at minimum a discharge summary and a current medication reconciliation list when transferring cardiovascular specialty care.